Health Stocks in Motion
Biopure (BPURD) rose 19.5% after it said the U.S. Naval Medical Research Center has applied to the FDA for approval to conduct a two-stage clinical trial of the company's oxygen therapeutic Hemopure drug for the out of hospital treatment of trauma patients, where blood is not available for transfusion.
If the trial is approved, the phase II and III of the study will assess the safety and efficacy of Hemopure compared with standard treatment of hemorrhagic shock (acute blood loss). Patients would be randomized to receive either Hemopure or standard therapy of the injury and during transport to the hospital. The company said the trial would require an exception from informed consent and would include a community consultation and disclosure program, as defined in federal regulations. To date, Congress has appropriated $18.5 million to the military to develop Hemopure for potential military and civilian use. Biopure Corporation develops and manufacturers intravenously administered pharmaceuticals, called oxygen therapeutics. The stock finished up 26 cents to $1.59.
Other health stocks on the move were Merck (MRK), up 16 cents to $31.55; Pfizer (PFE), up 21cents to $27.89; Elan (ELN), down 35 cents to $6.78; Biogen, down 22 cents to $34.79; and Johnson & Johnson (JNJ), down a penny to $66.47.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV